Abstract
Objective:
Explore the connection between serum levels of fibroblast growth factor 21 (FGF21) and platelet response protein 2 (TSP2) and the prognosis of older people with chronic heart failure. Also, look at how useful it is to detect these two markers together in predicting clinical prognosis to provide a theoretical basis for risk stratification and personalized treatment of chronic heart failure.
Method:
A prospective cohort study design was adopted. Included were 210 senior patients (65 years of age or older) with chronic heart failure who were hospitalized to the cardiology department of a particular hospital. Based on the patients' serum levels of TSP2 and FGF21. Low FGF21 and low TSP2 groups, low FGF21 and high TSP2 groups, high FGF21 and low TSP2 groups, and high FGF21 and high TSP2 groups. Enzyme-linked immunosorbent assay (ELISA) was used to measure the patients' serum levels of FGF21 and TSP2. Major adverse cardiovascular events (MACE), such as worsening heart failure, myocardial infarction, stroke, and cardiovascular mortality, were documented over the two-year follow-up period for each patient. A receiver operating characteristic (ROC) curve was created to assess the predictive value after the association between blood FGF21 and TSP2 levels and prognosis was examined using a Cox proportional hazards regression model.
Results:
Elderly patients with chronic heart failure had significantly higher serum levels of FGF21 and TSP2, which were positively linked with the NYHA cardiac function classification (P < 0.05). The high FGF21 and high TSP2 groups had a considerably higher incidence of MACEs than the other three groups (P < 0.05). Serum FGF21 and TSP2 levels were found to be independent indicators of outcome in older individuals with chronic heart failure by multivariate Cox regression analysis (HR = 2.38, 95% CI: 1.45–3.82, P < 0.01; HR = 1.91, 95% CI: 1.24–3.25, P < 0.05). The area under the curve (AUC) for predicting the occurrence of MACEs by the combined detection of serum FGF21 and TSP2 was 0.86 (95% CI: 0.79–0.82), which was significantly better than that of single marker detection (P < 0.05).
Conclusion:
The prognosis and cardiac function status of elderly patients with chronic heart failure are strongly correlated with serum levels of FGF21 and TSP2. In addition to being a crucial biomarker for risk assessment and tailored care of older individuals with chronic heart failure, combined detection can improve the predictive value for adverse cardiovascular events in these patients.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.